195314-59-1

Basic information

• Product Name: N-Boc-1,4-cyclohexanediamine
• Synonyms: (4-AMINO-CYCLOHEXYL)-CARBAMIC ACID TERT-BUTYL ESTER;1-BOC-AMINO-1,4-CYCLOHEXANEDIAMINE;1-N-BOC-1,4-CYCLOHEXANEDIAMINE;N-BOC-1,4-DIAMINECYCLOHEXANE;Trans-N-box-1,4-cyclohexanediamine;BUTYL 4-AMINOCYCLOHEXYLCARBAMATE;Boc-1,4-trans-DACH*HCl;trans-1,4-Diaminocyclohexane, N1-BOC protected
• CAS NO: 195314-59-1
• Molecular Formula: C₁₁H₂₂N₂O₂
• Molecular Weight: 214.3
• Product Categories: pharmacetical
• Mol File: 195314-59-1.mol

Chemical Properties

• Boiling Point: 322.073 °C at 760 mmHg
• Flash Point: 148.585 °C
• Appearance: White/Solid
• Density: 1.029 g/cm³
• Vapor Pressure: 0.000286mmHg at 25°C
• Refractive Index: 1.488
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 12.44±0.40(Predicted)
• CAS DataBase Reference: N-Boc-1,4-cyclohexanediamine(CAS DataBase Reference)
• NIST Chemistry Reference: N-Boc-1,4-cyclohexanediamine(195314-59-1)
• EPA Substance Registry System: N-Boc-1,4-cyclohexanediamine(195314-59-1)

Safety Data

• Hazard Codes: Xi,N
• Statements: 51/53
• Safety Statements: 61
• RIDADR: UN 3077 9 / PGIII
• WGK Germany: 3
• HazardClass: 8
• Hazardous Substances Data: 195314-59-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
N-Boc-1,4-cyclohexanediamine is used as a building block for the synthesis of pharmaceutical compounds. The Boc group protects the amine functionality, allowing for selective reactions to occur at other sites on the molecule, which is crucial for the creation of complex drug structures.
Used in Organic Chemistry Reactions:
In the field of organic chemistry, N-Boc-1,4-cyclohexanediamine is employed as a reagent. Its Boc-protected amine group facilitates controlled reactions, preventing unwanted side reactions that could occur if the amine were unprotected, thus enhancing the yield and purity of the desired products.
Used in Research and Development:
N-Boc-1,4-cyclohexanediamine is utilized in research and development settings as a versatile intermediate for exploring new chemical pathways and synthesizing novel compounds with potential applications in various industries, including pharmaceuticals, materials science, and agrochemicals.
Used in the Production of Active Pharmaceutical Ingredients (APIs):
As an important intermediate, N-Boc-1,4-cyclohexanediamine is used in the synthesis of APIs, contributing to the development of new medications and the improvement of existing ones. Its role in protecting the amine group is essential for the successful synthesis of complex molecular structures required for effective drug action.

InChI:InChI=1/C11H22N2O2/c1-11(2,3)15-10(14)13-9-6-4-8(12)5-7-9/h8-9H,4-7,12H2,1-3H3,(H,13,14)/t8-,9+

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 3114-70-3 trans-1,4-diaminocyclohexane 
• 582333-06-0 (4-azido-cyclohexyl)-carbamic acid tert-butyl ester 
• 2615-25-0 trans-1,4-cyclohexyldiamine 
• 224309-64-2 tert-butyl N-(4-hydroxycyclohexyl)carbamate 
• 6850-65-3 p-hydroxycyclohexylamine 

Downstream Products

• 1056938-23-8 C₂₅H₄₂ClN₇O₄ 
• 1011483-31-0 (4-tert-butoxycarbonylamino-cyclohexyl)-carbamic acid phenyl ester 
• 1011733-35-9 (R)-3-[4-(4-tert-butoxycarbonylamino-cyclohexylamino)-[1,3,5]triazin-2-ylamino]-pyrrolidine-1-carboxylic acid allyl ester 
• 866396-80-7 [4-(6-methoxy-3-nitro-pyridin-2-ylamino)-cyclohexyl]-carbamic acid tert-butyl ester 
• 582332-90-9 anti-{4-[(2-Chloro-5-fluoro-pyridine-3-carbonyl)amino]-cyclohexyl}-carbamic acid tert-butyl ester 
• 1932261-28-3 N-Methyl-cyclohexane-1,4-diamine 
• 227017-81-4 tert-butyl trans-4-(benzylamino)cyclohexylcarbamate 
• 1036712-15-8 [4-(isoquinolin-6-ylamino)-cyclohexyl]-carbamic acid tert-butyl ester 
• 1043962-51-1 tert-butyl (4-(2-nitrophenylcarbonylamino)cyclohexyl)carbamate 

Relevant articles and documents

POLYCYCLIC COMPOUNDS AS INHIBITORS OF BRUTON'S TYROSINE KINASE

The present disclosure is directed to compounds of Formula (I) as Bruton's kinase inhibitors and their preparation, as well as compositions comprising compounds of Formula (I).

Novel 5-anilinoquinazoline-8-nitro derivatives as inhibitors of VEGFR-2 tyrosine kinase: Synthesis, biological evaluation and molecular docking

Vascular endothelial growth factor receptor-2 (VEGFR-2) kinase inhibition is a well-established strategy to promptly tackle tumor growth by suppression of angiogenesis. We report herein a series of 5-anilinoquinazoline derivatives substituted by 1,3-disubstituted urea. All the newly synthesized compounds described were evaluated for VEGFR-2 kinase inhibition and antiproliferative activity against various cancer cells. The novel 1-aryl, 3-aryl-disubstituted urea quinazolines were effective VEGFR-2 kinase inhibitors with in vitro IC 50 values in the submicromolar range (compound 6f, IC50 12.0 nM), but showed a weak to moderate inhibitory activity on cancer cells. Molecular interactions of the compounds were studied using molecular docking studies. The Royal Society of Chemistry 2013.

CYCLOHEXYLAMINES, PHENYLAMINES AND USES THEREOF

Compounds having the formula I, their methods of synthesis, and pharmaceutically acceptable salts of certain of them are provided in which the variables have the definitions described herein. Compositions including the compounds having the formula I-A in

SOLUBLE EPOXIDE HYDROLASE INHIBITORS

Disclosed are amide, thioamide, urea and thiourea compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The co

Nucleic-acid triggered release of molecules

It is an object of the present invention to provide a method for highly selectively releasing a molecule of interest such as an agent at a desired site while suppressing the influence of catabolic enzymes existing in vivo. The present invention provides a

Small organic molecule regulators of cell proliferation

The present invention makes available methods and reagents for modulating proliferation or differentiation in a cell or tissue comprising contacting the cell with a hedgehog agonist, such as the compounds depicted in FIGS. 32 and 33. In certain embodiments, the methods and reagents may be employed to correct or inhibit an aberrant or unwanted growth state, e.g., by antagonizing a normal ptc pathway or agonizing smoothened or hedgehog activity.

NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS

This invention relates to nicotinamide derivatives of formula (I) and to pharmaceutical compositions containing, and the uses of such derivatives as PDE4 inhibitors wherein R7 is attached to the 3-or 4-position of the phenyl ring and is S(O)pR8, R8 is (C1-C4)alkyl optionally substituted by (C3-C6)cycloalkyl; m is 0 or 1; L is a (C3-C8)carbocyclic non-aromatic ring; and the remaining variables are as defined in the claims.

Small organic molecule regulators of cell proliferation

A compound represented in general formula (X) and (XI):

Small organic molecule regulators of cell proliferation

The present invention makes available methods and reagents for modulating proliferation or differentiation in a cell or tissue comprising contacting the cell with a hedgehog agonist, such as the compounds depicted in FIGS. 32 and 33. In certain embodiments, the methods and reagents may be employed to correct or inhibit an aberrant or unwanted growth state, e.g., by antagonizing a normal ptc pathway or agonizing smoothened or hedgehog activity.

Nicotinamide derivatives and a tiotropium salt in combination for the treatment of diseases

The invention relates to a combination of a nicotinamide derivative and tiotropium or a derivative thereof, compositions containing it and the uses of, such a combination. The combination according to the present invention is useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.